Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $18.6 million.

  • Ani Pharmaceuticals' Prepaid Assets rose 615.74% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year increase of 615.74%. This contributed to the annual value of $18.0 million for FY2024, which is 330.46% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Prepaid Assets of $18.6 million as of Q3 2025, which was up 615.74% from $15.1 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Prepaid Assets peaked at $23.3 million during Q1 2025, and registered a low of $4.7 million during Q3 2021.
  • For the 5-year period, Ani Pharmaceuticals' Prepaid Assets averaged around $11.4 million, with its median value being $8.4 million (2022).
  • Its Prepaid Assets has fluctuated over the past 5 years, first plummeted by 1102.77% in 2023, then surged by 13348.85% in 2024.
  • Ani Pharmaceuticals' Prepaid Assets (Quarter) stood at $7.6 million in 2021, then grew by 10.52% to $8.4 million in 2022, then soared by 107.46% to $17.4 million in 2023, then rose by 3.3% to $18.0 million in 2024, then rose by 3.2% to $18.6 million in 2025.
  • Its last three reported values are $18.6 million in Q3 2025, $15.1 million for Q2 2025, and $23.3 million during Q1 2025.